Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy PF-00562271
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable PF-00562271 Preclinical - Cell line xenograft Actionable In a preclinical study, PF-00562271 inhibited PTK2 (FAK) phosphorylation and growth of multiple tumor cell types in cell line xenograft models (PMID: 18339875). 18339875
Unknown unknown Advanced Solid Tumor not applicable PF-00562271 Phase I Actionable In a Phase I trial, PF-00562271 was well-tolerated and resulted in stable disease in 34% (31/91) of patients with advanced solid tumors as well as a metabolic response of 50% (7/14) (PMID: 22454420). 22454420
PubMed Id Reference Title Details
(18339875) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Full reference...
(22454420) Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Full reference...